- The HOPE randomized controlled trial (RCT) finds that postmenopausal hormone receptor (HR)-positive early breast cancer (eBCa) patients with aromatase inhibitor (AI)-induced arthralgias have better QoL with a 1-year gym-based, supervised exercise intervention than do usual-care control patients.
Why this matters
- HOPE findings suggest that the intervention may prevent treatment discontinuation and increase adherence to AIs.
- RCT of exercise, strength training vs usual care in 121 breast cancer survivors receiving AIs and having at least mild arthralgia (defined as a score ≥3 on the Brief Pain Inventory).
- The intervention consisted of 150 minutes of aerobic exercise and 2 strength training sessions each week for 1 year.
- The main assessment of QoL was by the Functional Assessment of Cancer Therapy (FACT) questionnaire and its subscales.
- Funding: NIH; Breast Cancer Research Foundation; Yale Cancer Center.
- The exercise group at 12 months had larger improvement than usual care in the following:
- Overall QoL (27-item FACT-General): 8.0 vs 1.2; P=.002.
- Breast cancer subscale (27-item FACT-G+10-item breast cancer scale): 2.2 vs 0.7; P=.03.
- Endocrine subscale (19-item FACT-ES): 5.5 vs 1.7; P=.003.
- Fatigue (13-item Functional Assessment of Chronic IIlness Therapy [FACIT]-Fatigue): 5.7 vs 0.5; P=.0003.
- Most outcomes were stronger at 12 than 6 months.
- All items self-reported with potential recall bias.